InvestorsHub Logo

MWM

Followers 1062
Posts 141582
Boards Moderated 14
Alias Born 03/31/2006

MWM

Re: None

Friday, 11/13/2020 7:03:52 AM

Friday, November 13, 2020 7:03:52 AM

Post# of 42611
Roth Capital maintained its Buy rating on Humanigen with a $25 per share price target, based upon its estimated risk-adjusted 2021 revenue for lenzilumab of approximately $700 million.